Logo.png
Vyant Bio Announces Investor Conference Call and Webcast for First Quarter 2021
13 mai 2021 08h00 HE | Vyant Bio, Inc.
CHERRY HILL, N.J., May 13, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), is focused on integrating human-powered scientific and technology-based systems to...
Logo.png
Vyant Bio to Present at BioNJ’s 11th Annual BioPartnering Conference
11 mai 2021 16h36 HE | Vyant Bio, Inc.
CHERRY HILL, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), is a new force in drug discovery, focused on integrating human-powered scientific and...
Logo.png
Vyant Bio, Inc., Ordaōs Bio, and Cellaria, Inc. Announce Collaboration to Design and Qualify Biomarker-Specific Small Protein Therapeutics
22 avr. 2021 08h00 HE | Vyant Bio, Inc.
New collaboration mitigates risk in drug discovery process with artificial intelligence and in vitro “avatar” clinical trials CHERRY HILL, N.J., April 22, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc....
Logo.png
Cancer Genetics and StemoniX Announce Merger Closing
31 mars 2021 06h30 HE | Cancer Genetics, Inc.
Cancer Genetics, Inc. Renamed to Vyant Bio, Inc. Vyant Bio, Inc. will begin trading on Nasdaq under the symbol VYNT CHERRY HILL, N.J., March 31, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc....